Sofinnova

Qorium Bolsters Board With Appointment of Elizabeth Bastoni and Martin Brok, Renowned Experts in the Consumer Goods and Retail Sectors

Retrieved on: 
tisdag, maj 21, 2024
Other Retail, Manufacturing, Luxury, Other Consumer, Fashion, Agriculture, Natural Resources, Retail, Textiles, Home Goods, Consumer, Burger King, The Coca-Cola Company, Human Capital, Communication, Starbucks, Sofinnova, CNH Industrial, Advent International, Compensated emancipation, Primark, CHRO, Chairperson, Audit committee, Sephora, Central Waqf Council, Brok, Oatly, Nike, Management

Qorium , the world-leading cell-cultured leather company, today announces the appointment of Elizabeth Bastoni as Board Chair and Martin Brok as member of its Board of Directors.

Key Points: 
  • Qorium , the world-leading cell-cultured leather company, today announces the appointment of Elizabeth Bastoni as Board Chair and Martin Brok as member of its Board of Directors.
  • With their extensive expertise and leadership, Bastoni and Brok will play pivotal roles in guiding the Board of this pioneering business.
  • Elizabeth Bastoni is an experienced Board Chair, Lead Independent Director, and former CHRO with a successful track record in the consumer goods, tech, and retail sectors.
  • Bastoni has a sharp focus on creating value at the intersection of business and people.

May Health Raises $25 Million in Series B Funding to Advance Development for Ovarian Rebalancing Therapy

Retrieved on: 
måndag, maj 13, 2024
Health, Medical Devices, Consumer, Women, Baby, Maternity, Clinical Trials, Biotechnology, Fertility, Polycystic ovary syndrome, Patient, PCOS, Sofinnova, OBGYN, Insulin resistance, Stroke, MD, Menstruation, Ovulation, Research, Androgen, Ovary, Woman, Infertility, Acne, IVF, Estrogen, Hand, Series, Female, Birth control

Funds will be used to support the company’s growth and advance its Ovarian Rebalancing™ therapy through the pivotal REBALANCE Study, evaluating its potential to address PCOS-related infertility.

Key Points: 
  • Funds will be used to support the company’s growth and advance its Ovarian Rebalancing™ therapy through the pivotal REBALANCE Study, evaluating its potential to address PCOS-related infertility.
  • From fertility challenges to emotional well-being and physical symptoms, women with PCOS need more viable treatment options,” said Anne Morrissey, CEO of May Health.
  • The straightforward, one-time in-office procedure is designed to induce ovulation through targeted ablation of ovarian tissue using radiofrequency (RF) energy.
  • We’re thankful to our investment partners for their support and look forward to further research of Ovarian Balancing in the REBALANCE Study.”

Sofinnova Partners Appoints Two New Partners Strengthening Team of Next Generation Investors

Retrieved on: 
måndag, april 22, 2024
Professional Services, Health, Other Professional Services, Environment, Sustainability, Other Health, Finance, Baxter, Sofinnova, Biotechnology, Chemical industry, Doctor of Philosophy, Growth, Imperial College London, Myocardial infarction, Heart failure, Renewable energy

These promotions underscore Sofinnova's dedication to developing talent from within its own ranks and commitment to driving impactful change in the sector.

Key Points: 
  • These promotions underscore Sofinnova's dedication to developing talent from within its own ranks and commitment to driving impactful change in the sector.
  • Gkelou joined Sofinnova as an Analyst in the Capital Strategy in 2017 after working as an immunology scientist at Danone Nutricia.
  • As a Partner in the Capital Strategy, Gkelou will play a key role in investing in the next generation of early-stage biotech companies.
  • "I am honored to have been part of the Industrial Biotechnology team since its early days," Baxter said.

EQS-News: Abivax reports 2023 financial results and operational update

Retrieved on: 
onsdag, april 10, 2024
Q&A, Nomination, New Drug Application, Patient, Shanda, MRO, G&A, IND, EQT, Marketing, Research, EST, McKinsey & Company, Carcinoma, Schering-Plough, Partnership, Webcast, SVP, IBD, Inflammatory Bowel Diseases, American College, Safety, Phase 10, Compensated emancipation, BB Biotech, URD, IPO, F2G, Sofinnova, FDA, AbbVie, EUR, Abstract, Takeda, Pharmaceutical industry

Total number of employees at the end of December 2023 was 61 and significantly increased compared to 2022, due to the implementation of the U.S. and European operational infrastructure.

Key Points: 
  • Total number of employees at the end of December 2023 was 61 and significantly increased compared to 2022, due to the implementation of the U.S. and European operational infrastructure.
  • Cash position (including other financial assets of EUR 9.0M) at the end of 2023 was EUR 261.0M, compared to EUR 27.0M at the end of 2022.
  • A webcast will be organized on Monday, April 8, 2024, at 2:30 p.m. CEST (8:30 a.m. EST) following the announcement of the 2023 yearly results.
  • The Abivax management will give an overview of the Company’s 2023 highlights and projects going forward, followed by a live Q&A session.

Abivax reports 2023 financial results and operational update

Retrieved on: 
tisdag, april 2, 2024
Q&A, Nomination, New Drug Application, Patient, Shanda, MRO, G&A, IND, EQT, Marketing, Research, EST, McKinsey & Company, Carcinoma, Schering-Plough, Partnership, Webcast, SVP, IBD, Inflammatory Bowel Diseases, American College, Safety, Phase 10, Compensated emancipation, BB Biotech, URD, IPO, F2G, Sofinnova, FDA, AbbVie, EUR, Abstract, Takeda, Pharmaceutical industry

Total number of employees at the end of December 2023 was 61 and significantly increased compared to 2022, due to the implementation of the U.S. and European operational infrastructure.

Key Points: 
  • Total number of employees at the end of December 2023 was 61 and significantly increased compared to 2022, due to the implementation of the U.S. and European operational infrastructure.
  • Cash position (including other financial assets of EUR 9.0M) at the end of 2023 was EUR 261.0M, compared to EUR 27.0M at the end of 2022.
  • A webcast will be organized on Monday, April 8, 2024, at 2:30 p.m. CEST (8:30 a.m. EST) following the announcement of the 2023 yearly results.
  • The Abivax management will give an overview of the Company’s 2023 highlights and projects going forward, followed by a live Q&A session.

Sensorion Announces a €15 Million Financing, Extending Cash Runway Until the End of 2025

Retrieved on: 
måndag, april 8, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, Other Health, SVB Securities, Stifel, EUR, GJB2, Euronext Growth, Patient, Code, Interim, Reserved, Sofinnova, Clinical trial, Commercial code, Person

The settlement-delivery of the Reserved Offering is expected to take place around April 11, 2024, subject to customary conditions.

Key Points: 
  • The settlement-delivery of the Reserved Offering is expected to take place around April 11, 2024, subject to customary conditions.
  • This builds on the earlier EUR 50 million financing announced in February 2024, adding up to a total of EUR 100 million raised in less than 9 months.
  • The capital increase enables the Company to finance its activities until the end of 2025.
  • Leerink Partners LLC (“Leerink Partners”) and Stifel Europe AG (“Stifel”) are acting as lead agents in connection with the Reserved Offering.

Synthace Announces Appointment of Willem Baralt as New Chairman

Retrieved on: 
onsdag, mars 20, 2024
Quanta, Automation, Growth, History, IPO, Doctor of Philosophy, Sofinnova, FDA, Fine chemical

LONDON and BOSTON, March 20, 2024 /PRNewswire/ -- Synthace , the leading digital experiment platform for life science R&D, today announced the appointment of Willem Baralt as its new Chairman of the Board.

Key Points: 
  • LONDON and BOSTON, March 20, 2024 /PRNewswire/ -- Synthace , the leading digital experiment platform for life science R&D, today announced the appointment of Willem Baralt as its new Chairman of the Board.
  • Mr. Baralt joined the company in February 2024 during a period of accelerating growth, as Synthace expands its offerings.
  • "I am thrilled to welcome Willem aboard," said Guy Levy-Yurista, PhD, CEO of Synthace.
  • "We welcome Willem Baralt's appointment as Chairman of the Board," said Joe Anderson, PhD, Partner at Sofinnova Partners.

Synthace Announces Appointment of Willem Baralt as New Chairman

Retrieved on: 
onsdag, mars 20, 2024
Quanta, Automation, Growth, History, IPO, Doctor of Philosophy, Sofinnova, FDA, Fine chemical

LONDON and BOSTON, March 20, 2024 /PRNewswire/ -- Synthace , the leading digital experiment platform for life science R&D, today announced the appointment of Willem Baralt as its new Chairman of the Board.

Key Points: 
  • LONDON and BOSTON, March 20, 2024 /PRNewswire/ -- Synthace , the leading digital experiment platform for life science R&D, today announced the appointment of Willem Baralt as its new Chairman of the Board.
  • Mr. Baralt joined the company in February 2024 during a period of accelerating growth, as Synthace expands its offerings.
  • "I am thrilled to welcome Willem aboard," said Guy Levy-Yurista, PhD, CEO of Synthace.
  • "We welcome Willem Baralt's appointment as Chairman of the Board," said Joe Anderson, PhD, Partner at Sofinnova Partners.

Cure51 raises a €15 million seed round to harness the natural power of cancer survivors and contribute to cure this life threatening disease

Retrieved on: 
onsdag, mars 20, 2024
International SOS, Disease, Partnership, International, Patient, Hospitality, Cancer, Vall, Medicine, Statistics, CLB, Survivor, Glioblastoma, Pancreatic cancer, IGR, Sofinnova, Pharmaceutical industry

Other investors included: Hitachi Ventures GmbH, Life Extension Ventures, Xavier Niel, and Olivier Pomel, CEO, and co-founder of Datadog.

Key Points: 
  • Other investors included: Hitachi Ventures GmbH, Life Extension Ventures, Xavier Niel, and Olivier Pomel, CEO, and co-founder of Datadog.
  • Key to this endeavor are the new analytical techniques and the strong partnership the company has forged with leading oncology centers worldwide.
  • The aim is to pioneer the creation of the world's first global clinical and molecular database of cancer survivors, by rewriting the narrative of cancer.
  • Rather than focusing on the disease mechanisms, Cure51 studies outliers – those individuals who defy statistics and miraculously survive the most aggressive forms of cancer, including metastatic stage pancreatic cancer and glioblastoma.

Cure51 raises a €15 million seed round to harness the natural power of cancer survivors and contribute to cure this life threatening disease

Retrieved on: 
onsdag, mars 20, 2024
Disease, Partnership, Patient, Cancer, Vall, Medicine, Statistics, CLB, Survivor, Glioblastoma, Pancreatic cancer, IGR, Sofinnova, Pharmaceutical industry

Other investors included: Hitachi Ventures GmbH, Life Extension Ventures, Xavier Niel, and Olivier Pomel, CEO, and co-founder of Datadog.

Key Points: 
  • Other investors included: Hitachi Ventures GmbH, Life Extension Ventures, Xavier Niel, and Olivier Pomel, CEO, and co-founder of Datadog.
  • Key to this endeavor are the new analytical techniques and the strong partnership the company has forged with leading oncology centers worldwide.
  • The aim is to pioneer the creation of the world's first global clinical and molecular database of cancer survivors, by rewriting the narrative of cancer.
  • Rather than focusing on the disease mechanisms, Cure51 studies outliers - those individuals who defy statistics and miraculously survive the most aggressive forms of cancer, including metastatic stage pancreatic cancer and glioblastoma.